comparemela.com

Latest Breaking News On - Michael strapazon - Page 5 : comparemela.com

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)

/PRNewswire/ Amgen (NASDAQ:AMGN) today announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG.

Puerto ricoColl cardiolMichael strapazonJessica akopyanDavidm reeseExchange commissionKyowa kirin co ltdTherapeutics incDrug administrationBeigene ltdTeneobio incStudy showed significantSustained reductionDuring treatment periodConsistent with phaseDow jones industrial average

AMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A DOUBLE TAKE TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesOak creekPuerto ricoMichael strapazonJessica akopyanLance bassExchange commissionKyowa kirin co ltdTherapeutics incBeigene ltdTeneobio incImmunotherapy centerCampaign drives awarenessPotential early symptomsPsoriatic arthritisEmpowers people

AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)

/PRNewswire/ Amgen (NASDAQ:AMGN) today announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER.

Puerto ricoUnited statesMichael strapazonJessica akopyanAmgen medinfoKyowa kirin co ltdBeigene ltdExchange commissionTherapeutics incEuropean unionTeneobio incStudies showed sustained reductionCombined studies evaluated safetyMore thanOver five years after completingLongest studied

AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)

/PRNewswire/ Amgen (NASDAQ:AMGN) today announced preliminary results from a Phase 3 study evaluating the efficacy and safety of ABP 654 compared to STELARA®.

United statesPuerto ricoMichael strapazonJessica akopyanKelley davenportDavidm reeseKyowa kirin co ltdDrug administrationBeigene ltdExchange commissionTherapeutics incEuropean unionNational psoriasis foundationTeneobio incPrimary efficacy analysis demonstratesClinically meaningful differences compared

AMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS 2022

/PRNewswire/ Amgen (NASDAQ: AMGN) today announced that new Otezla (apremilast) data, along with findings on the unmet need for patients with plaque.

United statesPuerto ricoMichael strapazonPalmoplantar pustulosisJessica akopyanKyowa kirin co ltdData on file at amgen incGlobal developmentDrug administrationBeigene ltdExchange commissionAmerican academy of dermatologyTherapeutics incNational psoriasis foundationTeneobio incAmerican academy

vimarsana © 2020. All Rights Reserved.